ストックスクリーナーアプリを入手
8.27
2.25%
-0.19
アフターアワーズ：
8.25
-0.02
-0.24%
前日終値:
$8.46
開ける：
$8.51
24時間の取引高:
173.57K
Relative Volume:
0.56
時価総額：
$662.53M
収益：
-
当期純損益:
$-83.12M
株価収益率:
-5.5292
EPS:
-1.4957
ネットキャッシュフロー:
$-114.50M
1週間 パフォーマンス:
-6.02%
1か月 パフォーマンス:
-7.18%
6か月 パフォーマンス:
-33.31%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$8.1489
$8.665
1週間の範囲:
$8.00
$9.00
52週間の値動き範囲:
$8.00
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
名前
Bridgebio Oncology Therapeutics Inc
セクター
電話
857 702 0377
住所
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
8.27 | 677.75M | 0 | -83.12M | -114.50M | -1.4957 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-11 | 開始されました | Stifel | Buy |
| 2026-01-09 | 開始されました | Raymond James | Outperform |
| 2025-12-05 | 開始されました | Morgan Stanley | Overweight |
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-09-15 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-15 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Bridgebio Oncology Therapeutics Inc (BBOT) 最新ニュース
[EFFECT] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock Price Today & Analysis - Gotrade
BBOT (NASDAQ: BBOT) registers 63.05M common shares for resale - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) accounting chief reports initial equity stake - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) COO Idan details initial stock and option holdings - Stock Titan
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media
63.05M shares registered; CEO change and consulting deal at BridgeBio Oncology (BBOT) - Stock Titan
Ex-CEO Wallace stays advisor at BridgeBio Oncology (BBOT) - Stock Titan
[ARS] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan
BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan
BridgeBio Oncology Therapeutics appoints new CEO and COO - MSN
Latest BBOT NewsBBOT Presents Preclinical Data Demonstratin... - Stock Titan
BridgeBio Oncology rises on Fast Track status for pancreatic cancer asset - MSN
H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy - Investing.com
Stifel Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
BridgeBio (BBOT) Stock: Price Pattern Formation | Q4 2025: EPS Beats ForecastsDividend Growth Rate - Xã Thanh Hà
BridgeBio Oncology Overhauls Leadership for Next Development Phase - TipRanks
BridgeBio Oncology names Pedro Beltran as new CEO By Investing.com - Investing.com India
BridgeBio Oncology Therapeutics (BBOT) registers 63.1M shares; Beltran named CEO - Stock Titan
New leadership team takes shape at BridgeBio Oncology (Nasdaq: BBOT) - Stock Titan
BBOT Presents Preclinical Data Demonstrating pan-KRAS - GlobeNewswire
BridgeBio Oncology names Pedro Beltran as new CEO - Investing.com
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman - marketscreener.com
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as - GlobeNewswire
BridgeBio Oncology presents preclinical data on BBO-10203 By Investing.com - Investing.com South Africa
BridgeBio Oncology presents preclinical data on BBO-10203 - Investing.com
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker - GlobeNewswire
BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution (NASDAQ:BBOT) - Seeking Alpha
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 - Yahoo Finance
Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT - Moomoo
BridgeBio Reports FDA Fast Track Label for BBO-11818 - Moomoo
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
BridgeBio Oncology Therapeutics stock jumps 10% on FDA nod By Investing.com - Investing.com Nigeria
BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment - marketscreener.com
FDA grants fast track status to BridgeBio’s pancreatic cancer drug By Investing.com - Investing.com Canada
BridgeBio Oncology Therapeutics, Inc recently revealed that the eagerly awaited updated data from its Phase I clinical trial is expected to be released in the second half of 2026. - Bitget
BridgeBio Oncology Therapeutics, Inc. (Bbot) announced that its innovative therapy Bbo-11818, for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma, has been granted Fast Track designation by the U.S. Food and Drug Administr - Bitget
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 - GlobeNewswire
Bridgebio Oncology Therapeutics Inc (BBOT) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):